Although speculative, the mechanisms involved may translate into substantial clinical benefits of BLX‐1002 in the management of type 2 diabetes – which differentiates it from most currently available antidiabetic drugs – by avoidance of prolonged hypoglycemia, lack of weight gain, selectivity for diabetic β‐cells, restoration of early GSIS and [Ca2+]i rise with attendant recovery of prandial glycemic control, and its suitability for combination therapy with sulfonylureas or GLP‐1‐based therapy. This evidence concerns the gene GLP1R and Hypoglycemia.